Hyderabad-based Bharat Biotech concluded a final analysis for its vaccine Covaxin efficacy from a phase-3 clinical trial, which claimed it to be 77.8 percent effective against COVID-19. It also states that Covaxin gives 65.2 percent protection against SARS-CoV-2, B.1.617.2 delta variant.
It was also found to be “93.4 per cent effective” against severe symptomatic COVID-19, the company said.
The pharma company recruited over 25,798 participants between November 16, 2020, and January 7, 2021, in what it called “India’s largest efficacy trial”. Of these, 24,419 were administered both doses.
The phase-3 analysis of Covaxin was reportedly carried out across 25 hospitals in the country as trial sites.
“We did a double-blind, randomised, multicentre, phase 3 clinical trial in 25 Indian hospitals 39 to evaluate the efficacy, safety, and immunological lot consistency of BBV152,” the paper explains.
Further, the safety results showed no cases of anaphylaxis or vaccine-related deaths were reported among those who took Covaxin.
It claims Covaxin has been evaluated through neutralizing antibody responses against several variants of concern, namely B.1.617.2 (Delta), B.1.617.1 (Kappa), B.1.1.7 (Alpha), B.1.351 (Beta), P2- B.1.1.28 (Gamma).
“No cases of anaphylaxis or vaccine-related deaths were reported. Interpretation: BBV152 was immunogenic and highly efficacious against symptomatic and asymptomatic COVID 19 variant associated disease, particularly against severe disease in adults,” it said.
(With ANI Inputs)
